GPRC5D 타깃 프로그램 | 바이오모아

Data Tier

ADC · Antibody · CGT를 FDA 승인, ORR·PASI·ACR·BCVA, 임상 등록 규모, Phase 3, 조회수 등 공개 데이터로 복합 점수화합니다. S–C 티어와 가점 요인은 규칙 기반(Data Tier)이며 LLM이 아닙니다.

RSS 구독 차세대 추천

이 조건에 티어를 산출할 프로그램이 없습니다.

프로그램 (6)

CGTBiologicstaleEssen BiotechPhase 2

BCMA/GPRC5D CAR-T cells (BCMA/GPRC5D CAR-T cells)

Multiple Myeloma; Multiple Myeloma in Relapse · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

CGTBiologicstaleDonghua ZhangPreclinical

Recurrent/refractory multiple myeloma (Recurrent/refractory multiple myeloma, Recurrent/refractory multiple myeloma (r/r MM) patients received infusion of BCMA-GPRC5D CAR-T cells, r/r MM)

Multiple Myeloma · BCMA

#BCMA#CGT#Preclinical#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

CGTBiologicstaleOriCell Therapeutics Co., Ltd.Phase 1

GPRC5D-CAR-T (GPRC5D-CAR-T)

Multiple Myeloma · GPRC5D

#GPRC5D#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 ACTIVE

CGTBiologicstale920th Hospital of Joint Logisti…Phase 2

Anti-GPRC5D CAR-T cells infusion (Anti-GPRC5D CAR-T cells infusion)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · GPRC5D

#GPRC5D#CGT#Phase2#세포유전치료#CAR-T+5

임상시험 1상태 ACTIVE

CGTBiologicBeijing BiotechPhase 2

Autologous BCMA/GPRC5D dual-target CAR-T (Autologous BCMA/GPRC5D dual-target CAR-T)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

CGTBiologicstaleO&D BioTech Group CO., LimitedPhase 1

Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D (Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D)

Relapsed or Refractory Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING